Learn more →
Back to Expert Scholars
thoracic-oncology / thoracic-oncologyImmunotherapy in NSCLC

Jhanelle E. Gray

贾内尔·格雷

MD

🏢Moffitt Cancer Center(莫菲特癌症中心)🌐USA

Senior Member and Chair, Department of Thoracic Oncology高级研究员;胸部肿瘤科主任

48
h-index
3
Key Papers
4
Awards
3
Key Contributions

👥Biography 个人简介

Dr. Jhanelle Gray is a leading thoracic oncologist specializing in immunotherapy and biomarkers for NSCLC. She leads Moffitt's thoracic oncology department and conducts pivotal trials on checkpoint inhibitors, TMB, and PD-L1 in lung cancer.

Share:

🧪Research Fields 研究领域

Thoracic Oncology胸部肿瘤学
NSCLC Immunotherapy非小细胞肺癌免疫治疗
Biomarkers生物标志物
PD-L1PD-L1
TMB肿瘤突变负荷

🎓Key Contributions 主要贡献

Immunotherapy Biomarker Development

Led research establishing tumor mutational burden (TMB) and PD-L1 expression as predictive biomarkers for checkpoint inhibitor response in NSCLC, supporting regulatory approval of companion diagnostics.

Checkpoint Inhibitor Clinical Trials

Key investigator on atezolizumab, nivolumab, and durvalumab trials in NSCLC, generating evidence that shapes immunotherapy sequencing and combination strategies in current practice.

Health Disparities in Lung Cancer

Researches racial and socioeconomic disparities in NSCLC outcomes and immunotherapy access, advocating for diverse clinical trial enrollment to ensure equitable benefit from immunotherapy advances.

Representative Works 代表性著作

[1]

Tumor Mutational Burden as a Biomarker for Immunotherapy in Non-Small-Cell Lung Cancer

Annals of Oncology (2019)

Characterized the predictive value of TMB across checkpoint inhibitor trials, contributing to FDA approval of pembrolizumab in high-TMB solid tumors.

[2]

Atezolizumab versus Docetaxel for Patients with Previously Treated NSCLC (OAK)

Lancet (2017)

Co-investigator on OAK trial demonstrating atezolizumab overall survival benefit over docetaxel, leading to second-line FDA approval in NSCLC.

[3]

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer (PACIFIC)

New England Journal of Medicine (2017)

Contributing investigator establishing durvalumab consolidation as standard of care after concurrent chemoradiation in unresectable stage III NSCLC.

🏆Awards & Recognition 奖项与荣誉

🏆ASCO Conquer Cancer Young Investigator Award
🏆Moffitt Cancer Center Distinguished Scientific Achievement Award
🏆American Cancer Society Institutional Research Grant
🏆IASLC Abstract Award

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 贾内尔·格雷 的研究动态

Follow Jhanelle E. Gray's research updates

留下邮箱,当我们发布与 Jhanelle E. Gray(Moffitt Cancer Center)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment